EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)

Matthew H Rim, Collin Dean, Enela Aliaj, Brittany L Karas, Farah Barada, Andrew M Levitsky

American Journal of Health-System Pharmacy · 2024

DOI: 10.1093/ajhp/zxae242 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Matthew H Rim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Drug Approval, United States Food and Drug Administration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by sharing new and anticipated novel drug approvals. Summary Selected drug approvals anticipated in the 12-month period covering the third quarter of 2024 through the second quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics selected from 54 novel drugs awaiting US Food and Drug Administration approval. New cell therapies for treating cancers continue to enter the drug pipeline, while novel targeted therapies for biliary tract, gastric, pancreatic, and breast cancers, as well as 3 subcutaneous versions of already approved drugs given intravenously, are awaiting approval. Additionally, many novel drugs are being developed for treatment of rare and ultra-rare diseases such as hereditary angioedema, macular telangiectasia, congenital adrenal hyperplasia, and Barth syndrome. Two new subcutaneous drugs for hemophilia, a new oral medication for hereditary angioedema, a novel monoclonal antibody for atopic dermatitis, and the first oral penem antibiotic are also in the pipeline.

Conclusion

New drugs with various indications for cancers and rare diseases continue to strengthen the drug pipeline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalUnited States Food and Drug AdministrationHumansUnited StatesPharmacistsProfessional RolePharmacy Service, Hospital

Stichwörter der Autor:innen

Food and Drug Administration drug approvalclinical trialsdrug approval processinvestigational drugsmedication developmentnew drug approvals

Autor:innen und Institutionen

  • Northwestern Medicine, Chicago, IL, USA.
  • IPD Analytics, Aventura, FL, USA.

Zitieren

APA

Rim, M. H., Dean, C., Aliaj, E., Karas, B. L., Barada, F., & Levitsky, A. M. (2024). Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025). American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae242

Vancouver

Rim MH, Dean C, Aliaj E, Karas BL, Barada F, Levitsky AM. Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025). American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxae242

BibTeX
@article{Rim2024,
  author = {Rim, Matthew H and Dean, Collin and Aliaj, Enela and Karas, Brittany L and Barada, Farah and Levitsky, Andrew M},
  title = {Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  doi = {10.1093/ajhp/zxae242}
}
Kostenlos starten →